Lumpy skin disease vaccine: Govt collaborates with Institute of Veterinary Biological Products for commercial production of Lumpi-ProVac

Lumpi-ProVac is used for the prophylactic immunization of animals against lumpy skin disease which gives protection for about one year.;

Published On 2023-01-02 06:05 GMT | Update On 2024-02-13 20:33 GMT

New Delhi: The government on Saturday said it has signed a pact with the Pune-based Institute of Veterinary Biological Products (IVBP) for commercial production of indigenously developed vaccine 'Lumpi-ProVac' for the control of lumpy skin disease in cattle.

The vaccine has been developed by the Haryana-based National Centre for Veterinary Type Culture and ICAR-National Research Centre on Equines in collaboration with Uttar Pradesh-based ICAR-Indian Veterinary Research Institute.

Agrinnovate India Ltd, the commercial arm of Department of Agriculture Research and Education under the aegis of Union Agriculture Ministry, has granted 'non-exclusive rights' for commercial production of 'Lumpi-ProVac' to IVPB for ten years, an official statement said.

After signing the memorandum of understanding (MoU), Union Minister of Fisheries, Animal Husbandry and Dairying Parshottam Rupala asked IVBP to "start manufacturing the vaccine at large scale without any delay."

Currently, the Goat Pox vaccine is used for controlling Lumpy Skin Disease in cattle. This MoU will also ensure large-scale production of Goat Pox vaccine for future needs of India's livestock sector, he said.

Maharashtra Chief Minister Eknath Shinde, Deputy CM Devendra Fadnavis, and state Animal Husbandry Minister Radhakrishna Vikhe Patil were present at the event.

"It is expected that the vaccine technology will definitely meet the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease," the statement said.

Lumpi-ProVac is used for the prophylactic immunization of animals against lumpy skin disease which gives protection for about one year. The vaccine is stored at 4 degree celsius and must be shipped on ice and used within a few hours after reconstitution. The patent has been filed by the ICAR for the technology, the statement added.

The Lumpy Skin Disease was reported in India in 2019, while the first case was reported in Odisha. After that, it has spread to multiple states across the country. In 2019, death of a large number of cattle was reported from different states with high morbidity, especially in the North-West region of the country.

The disease has been controlled and contained with the available Goat Pox vaccine in the country. Considering the heavy production losses and mortality of a sizable number of cattle, ICAR initiated research on development of indigenous homologous vaccine against Lumpy Skin Disease.

Indian Council of Agricultural Research Deputy Director General B N Tripathi and other top officials from IVRI, NRCE, and AgIn were also present at the event

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lumpy skin disease vaccine: Govt collaborates with Institute of Veterinary Biological Products for commercial production of Lumpi-ProVac

Lumpi-ProVac is used for the prophylactic immunization of animals against lumpy skin disease which gives protection for about one year.;

Similar News

Roche gets negative EMA Committee opinion on Elevidys CMA for 3-7 year olds with Duchenne muscular dystrophy

Expert Committee Clears Ravenbhel to Begin Resmetirom Phase 3 Trial, Asks for BE Data First

Menopause relief drug: USFDA extends review period for Bayer Elinzanetant

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Troikaa's Fast-Acting Paracetamol Shot Hits Regulatory Hurdle, CDSCO Panel Seeks More Data

Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma

Pharma Firm Ignored Safety Gaps Before Deadly Blast, Paid Rs 32 Cr To Victims, Parliament Informed

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma